Order Entry
Switzerland
ContactUsLinkComponent
Anti-ADAR Rabbit Polyclonal Antibody (Cy5®)
Katalognr. BOSSBS-2167R-CY5
Anbieter:  Bioss
Anti-ADAR Rabbit Polyclonal Antibody (Cy5®)
Katalognr. BOSSBS-2167R-CY5
Anbieter:  Bioss

Technische Daten

  • Antibody type:
    Primary
  • Antigen name:
    Adenosine deaminase, RNA-specific
  • Antigen symbol:
    ADAR
  • Clonality:
    Polyclonal
  • Conjugation:
    Cy5®
  • Host:
    Rabbit
  • ImmunoChemistry:
    Yes
  • Isotype:
    IgG
  • Reactivity:
    Human
  • Cross adsorption:
    No
  • Form:
    liquid
  • Gene ID:
    103
  • Antigen synonyms:
    ADAR1|K88DSRBP|IFI4|DRADA|DSRAD|AGS6|IFI-4|G1P1|DSH|P136
  • Storage buffer:
    Aqueous buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.
  • Storage temperature:
    Store at 4°C for 12 months
  • Concentration:
    1 μg/μl
  • Shipping temperature:
    4°C
  • Immunogen:
    150-200/1226
  • Purification:
    Purified by Protein A
  • Pk:
    100 µl

Technische Daten

Über diesen Artikel

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.

Recommended Dilutions: IF(IHC-P): 1:50-200

Type: Primary
Antigen: ADAR
Clonality: Polyclonal
Clone:
Conjugation: Cy5®
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human